Show simple item record

dc.contributor.authorO'Connor, James P Ben
dc.contributor.authorJayson, Gordon Cen
dc.date.accessioned2014-11-27T09:29:01Z
dc.date.available2014-11-27T09:29:01Z
dc.date.issued2012-12-15
dc.identifier.citationDo imaging biomarkers relate to outcome in patients treated with VEGF inhibitors? 2012, 18 (24):6588-98 Clin Cancer Resen
dc.identifier.issn1078-0432
dc.identifier.pmid23092875
dc.identifier.doi10.1158/1078-0432.CCR-12-1501
dc.identifier.urihttp://hdl.handle.net/10541/336200
dc.description.abstractThe management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, computed tomography (CT), and ultrasound to establish proof of principle. We have reviewed published studies that used these imaging techniques to determine whether the same biomarkers relate to survival in renal, hepatocellular, and brain tumors in patients treated with VEGF inhibitors. Data show that in renal cancer, pretreatment measurements of K(trans) and early pharmacodynamic reduction in tumor enhancement and density have prognostic significance in patients treated with VEGF inhibitors. A weaker, but significant, relationship is seen with subtle early size change (10% in one dimension) and survival. Data from high-grade glioma suggest that pretreatment fractional blood volume and K(trans) were prognostic of overall survival. However, lack of control data with other therapies prevents assessment of the predictive nature of these biomarkers, and such studies are urgently required.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.subject.meshAngiogenesis Inhibitors
dc.subject.meshAnimals
dc.subject.meshBrain Neoplasms
dc.subject.meshCarcinoma, Hepatocellular
dc.subject.meshCarcinoma, Renal Cell
dc.subject.meshGlioma
dc.subject.meshHumans
dc.subject.meshKidney Neoplasms
dc.subject.meshLiver Neoplasms
dc.subject.meshNeoplasms
dc.subject.meshTreatment Outcome
dc.subject.meshTumor Burden
dc.subject.meshTumor Markers, Biological
dc.subject.meshVascular Endothelial Growth Factor A
dc.titleDo imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?en
dc.typeArticleen
dc.contributor.departmentCentre for Imaging Sciences, University of Manchester, Manchester, United Kingdomen
dc.identifier.journalClinical Cancer Researchen
html.description.abstractThe management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, computed tomography (CT), and ultrasound to establish proof of principle. We have reviewed published studies that used these imaging techniques to determine whether the same biomarkers relate to survival in renal, hepatocellular, and brain tumors in patients treated with VEGF inhibitors. Data show that in renal cancer, pretreatment measurements of K(trans) and early pharmacodynamic reduction in tumor enhancement and density have prognostic significance in patients treated with VEGF inhibitors. A weaker, but significant, relationship is seen with subtle early size change (10% in one dimension) and survival. Data from high-grade glioma suggest that pretreatment fractional blood volume and K(trans) were prognostic of overall survival. However, lack of control data with other therapies prevents assessment of the predictive nature of these biomarkers, and such studies are urgently required.


This item appears in the following Collection(s)

Show simple item record